Comment on: Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

Comment on Werth et al., N Engl J Med 2022;387:321-31. DOI: 10.1056/NEJMoa2118024 Comment by Elisabet Svenungsson In clinical practice it is often a challenge to treat cutaneous lupus erythematosus (CLE), especially the discoid and chronic lesions are commonly very resistant to treatment. These lesions cause irreversible damage, which has great impact on the quality of … Read more